Storia in 2 fonti

How one biotech is using 'digital twins' to study a muscle disease therapy

Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI

Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321